However, in CLL, even if preclinical data had demonstrated an anti-tumor effect exerted by antibodies targeting PD-L1 or PD1 and LAG3 (15, 16), clinical trials have produced disappointing results (17, 18), and today ICI are rarely considered an option for patients with CLL. The gene discussed is CD274; the disease is neoplasm.